Milestone Pharmaceuticals Inc. Common Shares (MIST)

Price$1.36

Value ScoreD

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-54.46%

Price vs S&P 500 (4W)-29.04%

VGM Score26.89

Market Capitalization$176.79M

All Metrics

Book Value / Share (Quarterly)$0.31

P/TBV (Annual)1.39x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-32.38%

Cash Flow / Share (Quarterly)$-0.44

Price vs S&P 500 (YTD)-40.64%

Net Profit Margin (TTM)-2436.94%

EPS (TTM)$-0.68

10-Day Avg Trading Volume1.27M

EPS Excl Extra (TTM)$-0.68

EPS (Annual)$-0.75

ROI (Annual)-63.72%

Net Profit Margin (5Y Avg)-1148.11%

Cash / Share (Quarterly)$1.56

ROA (Last FY)-55.53%

EBITD / Share (TTM)$-0.65

ROE (5Y Avg)-189.76%

Operating Margin (TTM)-2293.72%

Cash Flow / Share (Annual)$-0.46

P/B Ratio4.90x

P/B Ratio (Quarterly)3.88x

Net Income / Employee (Annual)$-1,659,400

EV / Revenue (TTM)135.52x

Net Interest Coverage (TTM)-67.69x

ROA (TTM)-61.80%

EPS Incl Extra (Annual)$-0.75

Current Ratio (Annual)8.01x

Quick Ratio (Quarterly)9.03x

3-Month Avg Trading Volume1.98M

52-Week Price Return-10.69%

Revenue / Employee (TTM)$46,900

Tangible BV / Share (Quarterly)$0.85

P/S Ratio (Annual)114.35x

Asset Turnover (Annual)0.01x

52-Week High$3.06

Operating Margin (5Y Avg)-1175.64%

EPS Excl Extra (Annual)$-0.75

CapEx CAGR (5Y)-39.58%

Tangible BV CAGR (5Y)20.62%

26-Week Price Return-38.53%

Quick Ratio (Annual)7.83x

13-Week Price Return-17.44%

Total Debt / Equity (Annual)1.37x

Current Ratio (Quarterly)9.18x

Enterprise Value$241.77M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-39.38%

Revenue / Employee (Annual)$40,700

Pretax Margin (Annual)-4078.78%

Cash / Share (Annual)$1.00

3-Month Return Std Dev96.27%

Net Income / Employee (TTM)$-1,799,000

ROE (Last FY)-150.97%

Net Interest Coverage (Annual)-21.17x

EPS Basic Excl Extra (Annual)$-0.75

Receivables Turnover (TTM)3.31x

Total Debt / Equity (Quarterly)3.78x

EPS Incl Extra (TTM)$-0.68

Receivables Turnover (Annual)5.90x

ROI (TTM)-47.75%

P/S Ratio (TTM)99.10x

Pretax Margin (5Y Avg)-1148.11%

Revenue / Share (Annual)$0.02

Tangible BV / Share (Annual)$1.94

Price vs S&P 500 (52W)-38.90%

Year-to-Date Return-29.70%

5-Day Price Return0.71%

EPS Normalized (Annual)$-0.75

ROA (5Y Avg)-60.80%

Net Profit Margin (Annual)-4078.78%

Month-to-Date Return-21.11%

Cash Flow / Share (TTM)$-1.38

EBITD / Share (Annual)$-0.74

Operating Margin (Annual)-4019.40%

LT Debt / Equity (Annual)1.37x

ROI (5Y Avg)-68.40%

LT Debt / Equity (Quarterly)3.78x

EPS Basic Excl Extra (TTM)$-0.68

P/TBV (Quarterly)3.24x

P/B Ratio (Annual)4.12x

Pretax Margin (TTM)-2436.94%

Book Value / Share (Annual)$0.39

Price vs S&P 500 (13W)-27.19%

Beta0.97x

Revenue / Share (TTM)$0.01

ROE (TTM)-169.03%

52-Week Low$1.00

vGradeD

mGradeD

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.20est. 0.31

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.00

4.08

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
MISTMilestone Pharmaceuticals Inc. Common Shares	D	—	D	$1.36
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Milestone Pharmaceuticals is a biopharmaceutical company developing etripamil, a rapid-onset calcium channel blocker delivered as a nasal spray for cardiovascular conditions. The company is commercializing etripamil for paroxysmal supraventricular tachycardia (PSVT) treatment and has a Phase 2 clinical trial underway for atrial fibrillation with rapid ventricular rate (AFib-RVR).